247 related articles for article (PubMed ID: 28678044)
1. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy.
Jensen BES; Hansen JM; Larsen KS; Junker AB; Lassen JF; Jensen SE; Schaffalitzky de Muckadell OB
Eur J Gastroenterol Hepatol; 2017 Oct; 29(10):1118-1125. PubMed ID: 28678044
[TBL] [Abstract][Full Text] [Related]
2. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis.
Khan MY; Siddiqui WJ; Alvarez C; Aggarwal S; Hasni SF; Ahmad A; Eisen H
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):847-853. PubMed ID: 29596078
[TBL] [Abstract][Full Text] [Related]
3. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
[TBL] [Abstract][Full Text] [Related]
4. [The incidence, clinical characteristics and risk factors of upper gastrointestinal bleeding in patients taking dual antiplatelet therapy after percutaneous coronary intervention in south China].
Zhang ZF; Sha WH; Tan GY; Wang QY
Zhonghua Nei Ke Za Zhi; 2016 Jun; 55(6):445-50. PubMed ID: 27256606
[TBL] [Abstract][Full Text] [Related]
5. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
[TBL] [Abstract][Full Text] [Related]
6. Only full adherence to proton pump inhibitors protects against drug-induced upper gastrointestinal bleeding.
Ruiz B; Aguirre U; Estany-Gestal A; Rodella L; Ruiz P; Figueiras A; Carvajal A; Ibáñez L; Conforti A; de Pancorbo MM; Vidal X; Martin LH; Aguirre C
Eur J Clin Pharmacol; 2018 Nov; 74(11):1503-1511. PubMed ID: 30043109
[TBL] [Abstract][Full Text] [Related]
7. [Meta-analysis on safety and efficacy of dual antiplatelet therapy combining with proton pump inhibitors for patients after percutaneous coronary intervention].
Che QQ; Wu Q; Liang YB; Sun RM; Lyu QW; Ma JL; Hu H; Lin X; Xu GL; Sun SG; Zhang C; Wang QY; Yu J; Bai F
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Feb; 47(2):129-140. PubMed ID: 30818941
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of proton pump inhibitors on cardiovascular events and inflammatory factors in patients with upper gastrointestinal bleeding undergoing dual antiplatelet therapy.
Yang S; Shi L
Inflammopharmacology; 2024 Jun; 32(3):1999-2006. PubMed ID: 38642222
[TBL] [Abstract][Full Text] [Related]
9. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
Aihara H; Sato A; Takeyasu N; Nishina H; Hoshi T; Akiyama D; Kakefuda Y; Watabe H; Aonuma K;
Catheter Cardiovasc Interv; 2012 Oct; 80(4):556-63. PubMed ID: 22234956
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors receiving and prognosis of patients after scheduled percutaneous coronary interventions.
Komarov AL; Shakhmatova OO; Muraseeva VG; Novikova ES; Guskova EV; Panchenko EP
Ter Arkh; 2018 Sep; 90(9):92-100. PubMed ID: 30701742
[TBL] [Abstract][Full Text] [Related]
11. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review.
Melloni C; Washam JB; Jones WS; Halim SA; Hasselblad V; Mayer SB; Heidenfelder BL; Dolor RJ
Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):47-55. PubMed ID: 25587094
[TBL] [Abstract][Full Text] [Related]
12. Etiology of gastrointestinal bleeding in patients on dual antiplatelet therapy.
Shaukat A; Waheed S; Alexander E; Washko D; Dawn B; Olyaee M; Gupta K
J Dig Dis; 2018 Feb; 19(2):66-73. PubMed ID: 29314627
[TBL] [Abstract][Full Text] [Related]
13. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy.
Casado Arroyo R; Polo-Tomas M; Roncalés MP; Scheiman J; Lanas A
Heart; 2012 May; 98(9):718-23. PubMed ID: 22523056
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
Vaduganathan M; Cannon CP; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Bhatt DL;
Am J Med; 2016 Sep; 129(9):1002-5. PubMed ID: 27143321
[TBL] [Abstract][Full Text] [Related]
15. Meta-Analysis of Efficacy and Safety of Proton Pump Inhibitors with Dual Antiplatelet Therapy for Coronary Artery Disease.
Khan SU; Lone AN; Asad ZUA; Rahman H; Khan MS; Saleem MA; Arshad A; Nawaz N; Sattur S; Kaluski E
Cardiovasc Revasc Med; 2019 Dec; 20(12):1125-1133. PubMed ID: 30773427
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of ulcer bleeding risk factors in dual antiplatelet-treated patients after percutaneous coronary intervention.
Jensen BE; Hansen JM; Junker AB; Lassen JF; Jensen SE; Schaffalitzky de Muckadell OB
Dan Med J; 2015 Jun; 62(6):. PubMed ID: 26036886
[TBL] [Abstract][Full Text] [Related]
17. Effect of low-dose proton pump inhibitor on preventing upper gastrointestinal bleeding in chronic kidney disease patients receiving aspirin.
Lim H; Kim JH; Baik GH; Park JW; Kang HS; Moon SH; Park CK
J Gastroenterol Hepatol; 2015 Mar; 30(3):478-84. PubMed ID: 25252119
[TBL] [Abstract][Full Text] [Related]
18. Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
Häuptle R; Weilenmann D; Schneider T; Haile SR; Ammann P; Knellwolf C; Borovicka J
Wien Med Wochenschr; 2012 Feb; 162(3-4):67-73. PubMed ID: 22476595
[TBL] [Abstract][Full Text] [Related]
19. Continuous proton pump inhibitor treatment decreases upper gastrointestinal bleeding and related death in rural area in Japan.
Miyamoto M; Haruma K; Okamoto T; Higashi Y; Hidaka T; Manabe N
J Gastroenterol Hepatol; 2012 Feb; 27(2):372-7. PubMed ID: 21793917
[TBL] [Abstract][Full Text] [Related]
20. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
Gargiulo G; Costa F; Ariotti S; Biscaglia S; Campo G; Esposito G; Leonardi S; Vranckx P; Windecker S; Valgimigli M
Am Heart J; 2016 Apr; 174():95-102. PubMed ID: 26995375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
